

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original): An antibody comprising two heavy chain variable regions and two light chain variable regions, wherein the antibody is a single chain polypeptide having a binding activity against human leukocyte antigen (HLA).
2. (Original): The antibody of claim 1, wherein the two heavy chain variable regions and two light chain variable regions are arranged in the order of heavy chain variable region, light chain variable region, heavy chain variable region, and light chain variable region, starting from the N terminus of the single chain polypeptide.
3. (Previously presented): The antibody of claim 1, wherein the two heavy chain variable regions and two light chain variable regions are linked by a linker.
4. (Original): The antibody of claim 3, wherein the linker comprises 15 amino acids.
5. (Previously presented): The antibody of claim 1, wherein HLA is HLA class I.
6. (Original): The antibody of claim 5, wherein HLA class I is HLA-A.
7. (Previously presented): The antibody of claim 1, wherein the antibody is sc(Fv)2.

8. (Original): An sc(Fv)2 comprising heavy chain variable regions that comprise CDR1, 2, and 3 consisting of the amino acid sequences of SEQ ID NOs: 3, 4, and 5.

9. (Original): An sc(Fv)2 comprising light chain variable regions that comprise CDR 1, 2, and 3 consisting of the amino acid sequences of SEQ ID NOs: 6, 7, and 8.

10. (Original): An sc(Fv)2 comprising heavy chain variable regions that comprise CDR1, 2, and 3 consisting of the amino acid sequences of SEQ ID NOs: 3, 4, and 5, and light chain variable regions that comprise CDR 1, 2, and 3 consisting of the amino acid sequences of SEQ ID NOs: 6, 7, and 8.

11. – 16. (Canceled)

17. (Withdrawn): A polynucleotide encoding the antibody of claim 1.

18. (Withdrawn): A polynucleotide that hybridizes with the polynucleotide of claim 17 under stringent conditions, and encodes an antibody having a binding activity against human leukocyte antigen (HLA).

19. (Withdrawn): A vector comprising the polynucleotide of claim 17.

20. (Withdrawn): A host cell carrying the polynucleotide of claim 17.

21. (Withdrawn-currently amended): A method for producing the antibody of claim 1, wherein the method comprises the steps of:

(a) preparing an HLA-recognizing antibody;
(b) producing a vector comprising a polynucleotide encoding the antibody of claim 1 based on the sequence of the antibody prepared in (a);

~~(e) constructing a vector comprising the polynucleotide of (b);~~
(c) [[(d)]] introducing the vector of [[(c)]](b) into host cells; and
(d) [[(e)]] culturing the host cells of [[(d)]](c).

22. (Currently amended): ~~A cell death inducing agent pharmaceutical composition~~ comprising the antibody of claim 1 as an active ingredient.

23. (Currently amended): ~~The cell death inducing agent composition~~ of claim 22, wherein the agent has cell death inducing activity against B cells or T cells.

24. (Currently amended): ~~The cell death inducing agent composition~~ of claim 23, wherein the B cells or T cells are activated B cells or activated T cells.

25. – 28. (Canceled)

29. (New): The method of claim 21, wherein the antibody is sc(Fv)2, and the heavy chain variable regions comprise CDR1, 2, and 3 consisting of the amino acid sequences of SEQ ID NOS: 3, 4, and 5.

30. (New): The method of claim 21, wherein the antibody is sc(Fv)2, and the light chain variable regions comprise CDR1, 2, and 3 consisting of the amino acid sequences of SEQ ID NOS: 6, 7, and 8.

31. (New): The method of claim 21, wherein the antibody is sc(Fv)2; the heavy chain variable regions comprise CDR1, 2, and 3 consisting of the amino acid sequences of SEQ ID NOS: 3, 4, and 5; and the light chain variable regions comprise CDR1, 2, and 3 consisting of the amino acid sequences of SEQ ID NOS: 6, 7, and 8.

32. (New): A pharmaceutical composition comprising the sc(Fv)2 of claim 8 as an active ingredient.

33. (New): A pharmaceutical composition comprising the sc(Fv)2 of claim 9 as an active ingredient.

34. (New): A pharmaceutical composition comprising the sc(Fv)2 of claim 10 as an active ingredient.

35. (New): A method of treating a tumor in a subject in need thereof, comprising administering to the subject an effective dose of the pharmaceutical composition of claim 22, wherein the composition induces cell death or inhibits cell growth of a tumor in the subject.

36. (New): The method of claim 35, wherein the tumor is a blood tumor.

37. (New): A method of treating a tumor in a subject in need thereof, comprising administering to the subject an effective dose of the pharmaceutical composition of claim 32, wherein the composition induces cell death or inhibits cell growth of a tumor in the subject.

38. (New): The method of claim 37, wherein the tumor is a blood tumor.

39. (New): A method of treating a tumor in a subject in need thereof, comprising administering to the subject an effective dose of the pharmaceutical composition of claim 33, wherein the composition induces cell death or inhibits cell growth of a tumor in the subject.

40. (New): The method of claim 39, wherein the tumor is a blood tumor.

41. (New): A method of treating a tumor in a subject in need thereof, comprising administering to the subject an effective dose of the pharmaceutical composition of claim 34, wherein the composition induces cell death or inhibits cell growth of a tumor in the subject.

42. (New): The method of claim 41, wherein the tumor is a blood tumor.

43. (New): A method of treating an autoimmune disease in a subject in need thereof, comprising administering to the subject an effective dose of the pharmaceutical composition of claim 25, thereby treating the autoimmune disease in the subject.

44. (New): A method of treating an autoimmune disease in a subject in need thereof, comprising administering to the subject an effective dose of the pharmaceutical composition of claim 32, thereby treating the autoimmune disease in the subject.

45. (New): A method of treating an autoimmune disease in a subject in need thereof, comprising administering to the subject an effective dose of the pharmaceutical composition of claim 33, thereby treating the autoimmune disease in the subject.

46. (New): A method of treating an autoimmune disease in a subject in need thereof, comprising administering to the subject an effective dose of the pharmaceutical composition of claim 34, thereby treating the autoimmune disease in the subject.